True progression versus pseudoprogression in the treatment of glioblastomas: A comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis

Korean Journal of Radiology

Volumn 14, Issue 4, 2013, Pages 662-672

  Song, Yong Sub ^a   Choi, Seung Hong ^a   Park, Chul Kee ^a   Yi, Kyung Sik ^a   Lee, Woong Jae ^a   Yun, Tae Jin ^a   Kim, Tae Min ^a   Lee, Se Hoon ^a   Kim, Ji Hoon ^a   Sohn, Chul Ho ^a   Park, Sung Hye ^a   Kim, Il Han ^a   Jahng, Geon Ho ^b   Chang, Kee Hyun ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

Apparent diffusion coefficient; Cerebral blood volume; Glioblastoma multiforme; Histogram analysis; Pseudoprogression

Indexed keywords

CONTRAST MEDIUM; GADOBUTROL; TEMOZOLOMIDE;

ADULT; AGED; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; BRAIN BLOOD FLOW; CANCER GROWTH; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; FEMALE; GLIOBLASTOMA; HISTOGRAM; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; MALE; PERFUSION WEIGHTED IMAGING; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; SENSITIVITY AND SPECIFICITY;

APPARENT DIFFUSION COEFFICIENT; CEREBRAL BLOOD VOLUME; GLIOBLASTOMA MULTIFORME; HISTOGRAM ANALYSIS; PSEUDOPROGRESSION;

ADULT; AGED; BRAIN NEOPLASMS; CEREBROVASCULAR CIRCULATION; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REGIONAL BLOOD FLOW; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 84880779552     PISSN: 12296929     EISSN: None     Source Type: Journal    
DOI: 10.3348/kjr.2013.14.4.662     Document Type: Article

References (39)

1. Jeon HJ, Kong DS, Park KB, Lee JI, Park K, Kim JH, et al. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: singlecenter experience. Clin Neurol Neurosurg 2009;111:679-682
2. Erpolat OP, Akmansu M, Goksel F, Bora H, Yaman E, Büyükberber S. Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis. Tumori 2009;95:191-197
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996
4. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280
5. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, et al. Incidence of early pseudoprogression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113:405-410
6. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9:453-461
7. Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol 2009;72:423-428
8. Chamberlain MC. Pseudoprogression in glioblastoma. J Clin Oncol 2008;26:4359; author reply 4359-4360
9. Dooms GC, Hecht S, Brant-Zawadzki M, Berthiaume Y, Norman D, Newton TH. Brain radiation lesions: MR imaging. Radiology 1986;158:149-155
10. Morris JG, Grattan-Smith P, Panegyres PK, O'Neill P, Soo YS, Langlands AO. Delayed cerebral radiation necrosis. Q J Med 1994;87:119-129
11. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-1972
12. Hein PA, Eskey CJ, Dunn JF, Hug EB. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 2004;25:201-209
13. Asao C, Korogi Y, Kitajima M, Hirai T, Baba Y, Makino K, et al. Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. AJNR Am J Neuroradiol 2005;26:1455-1460
14. Matsusue E, Fink JR, Rockhill JK, Ogawa T, Maravilla KR. Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology 2010;52:297-306
15. Barajas RF Jr, Chang JS, Segal MR, Parsa AT, McDermott MW, Berger MS, et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009;253:486-496
16. Hu LS, Baxter LC, Smith KA, Feuerstein BG, Karis JP, Eschbacher JM, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009;30:552-558
17. Kong DS, Kim ST, Kim EH, Lim DH, Kim WS, Suh YL, et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol 2011;32:382-387
18. Zeng QS, Li CF, Liu H, Zhen JH, Feng DC. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusionweighted imaging. Int J Radiat Oncol Biol Phys 2007;68:151-158
19. Sugahara T, Korogi Y, Tomiguchi S, Shigematsu Y, Ikushima I, Kira T, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrastenhancing tissue. AJNR Am J Neuroradiol 2000;21:901-909
20. Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumabtreated glioblastoma. AJNR Am J Neuroradiol 2011;32:882-889
21. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252:182-189
22. Kim HS, Kim JH, Kim SH, Cho KG, Kim SY. Posttreatment high-grade glioma: usefulness of peak height position with semiquantitative MR perfusion histogram analysis in an entire contrast-enhanced lesion for predicting volume fraction of recurrence. Radiology 2010;256:906-915
23. Baek HJ, Kim HS, Kim N, Choi YJ, Kim YJ. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas. Radiology 2012;264:834-843
24. Kang Y, Choi SH, Kim YJ, Kim KG, Sohn CH, Kim JH, et al. Gliomas: histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging--correlation with tumor grade. Radiology 2011;261:882-890
25. Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249-265
26. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: mathematical approach and statistical analysis. Magn Reson Med 1996;36:715-725
27. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859-867
28. Wetzel SG, Cha S, Johnson G, Lee P, Law M, Kasow DL, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797-803
29. Bjornerud A. The ICE software package: direct co-registration of anatomical and functional datasets using DICOM image geometry information. Proc Hum Brain Mapping 2003;19:1018p
30. Tozer DJ, Jäger HR, Danchaivijitr N, Benton CE, Tofts PS, Rees JH, et al. Apparent diffusion coefficient histograms may predict low-grade glioma subtype. NMR Biomed 2007;20:49-57
31. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11:102-125
32. Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, et al. Usefulness of diffusion-weighted MRI with echoplanar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53-60
33. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004;63:535-537
34. Oh BC, Pagnini PG, Wang MY, Liu CY, Kim PE, Yu C, et al. Stereotactic radiosurgery: adjacent tissue injury and response after high-dose single fraction radiation: Part I--Histology, imaging, and molecular events. Neurosurgery 2007;60:31-44; discussion 44-45
35. Wesseling P, Ruiter DJ, Burger PC. Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neurooncol 1997;32:253-265
36. Cha S, Knopp EA, Johnson G, Litt A, Glass J, Gruber ML, et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 2000;21:881-890
37. Heiland S, Benner T, Debus J, Rempp K, Reith W, Sartor K. Simultaneous assessment of cerebral hemodynamics and contrast agent uptake in lesions with disrupted blood-brainbarrier. Magn Reson Imaging 1999;17:21-27
38. Spiegelmann R, Friedman WA, Bova FJ, Theele DP, Mickle JP. LINAC radiosurgery: an animal model. J Neurosurg 1993;78:638-644
39. Minamikawa S, Kono K, Nakayama K, Yokote H, Tashiro T, Nishio A, et al. Glucocorticoid treatment of brain tumor patients: changes of apparent diffusion coefficient values measured by MR diffusion imaging. Neuroradiology 2004;46:805-811